Pohl-Boskamp

Executive Summary

Pohl-Boskamp is a privately held, family-owned German pharmaceutical company headquartered in Hohenlockstedt, Schleswig-Holstein. The company specializes in branded generic drugs and digital health applications (DiGA), with all development and manufacturing conducted in Germany. Its products are marketed in approximately 50 countries worldwide, demonstrating a strong international footprint despite its medium-sized, independent status. The company's focus on high-quality generics and innovative digital therapeutics positions it well within the evolving healthcare landscape, particularly as DiGA gains traction in Germany's reimbursement system. As a private entity, Pohl-Boskamp maintains operational flexibility and a long-term strategic view, free from quarterly earnings pressures. Its integrated value chain—from R&D to production—enables quality control and agility. However, limited public disclosures make it challenging to assess financial performance or pipeline depth. Overall, Pohl-Boskamp represents a stable, niche player in the generic and digital health segments, with potential for steady growth driven by regulatory approvals and market expansion.

Upcoming Catalysts (preview)

• Q4 2026New DiGA (Digital Health Application) Listing Approval70% success
• 2027Expansion into New International Markets60% success
• Q2 2026Launch of New Branded Generic Product75% success